Blocking IL-1 signaling rescues cognition, attenuates Tau pathology, and restores neuronal -βcatenin pathway function in an Alzheimer's disease model

Journal of Immunology

Volumn 187, Issue 12, 2011, Pages 6539-6549

  Kitazawa, Masashi ^a,b   Cheng, David ^a,b   Tsukamoto, Michelle R ^a,b   Koike, Maya A ^a,b   Wes, Paul D ^c,d   Vasilevko, Vitaly ^a   Cribbs, David H ^a,b   LaFerla, Frank M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ROCHE BIOSCIENCE   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BETA CATENIN; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN P25; PROTEIN S100B; WNT PROTEIN;

ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENCEPHALITIS; ENTORHINAL CORTEX; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MICROGLIA; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; SUBICULUM; TAUOPATHY;

ALZHEIMER DISEASE; ANIMALS; BETA CATENIN; CELL LINE, TUMOR; CELLS, CULTURED; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INTERLEUKIN-1BETA; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NERVE GROWTH FACTORS; NEURONS; NF-KAPPA B; RECEPTORS, INTERLEUKIN-1; S100 PROTEINS; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 83755183781     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1100620     Document Type: Article

References (81)

1. Glass, C. K., K. Saijo, B. Winner, M. C. Marchetto, and F. H. Gage. 2010. Mechanisms underlying inflammation in neurodegeneration. Cell 140: 918-934.
2. Landreth, G. E., and E. G. Reed-Geaghan. 2009. Toll-like receptors in Alzheimer's disease. Curr. Top. Microbiol. Immunol. 336: 137-153.
3. Lee, Y. J., S. B. Han, S. Y. Nam, K. W. Oh, and J. T. Hong. 2010. Inflammation and Alzheimer's disease. Arch. Pharm. Res. 33: 1539-1556.
4. McGeer, P. L., M. Schulzer, and E. G. McGeer. 1996. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47: 425-432. (Pubitemid 26324038)
5. Breitner, J. C., B. A. Gau, K. A. Welsh, B. L. Plassman, W. M. McDonald, M. J. Helms, and J. C. Anthony. 1994. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 44: 227-232. (Pubitemid 24070956)
6. in t' Veld, B. A., A. Ruitenberg, A. Hofman, L. J. Launer, C. M. van Duijn, T. Stijnen, M. M. Breteler, and B. H. Stricker. 2001. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 345: 1515-1521.
7. Szekely, C. A., R. C. Green, J. C. Breitner, T. Østbye, A. S. Beiser, M. M. Corrada, H. H. Dodge, M. Ganguli, C. H. Kawas, L. H. Kuller, et al. 2008. No advantage of Aβ42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 70: 2291-2298.
8. Bauer, J., S. Strauss, U. Schreiter-Gasser, U. Ganter, P. Schlegel, I. Witt, B. Yolk, and M. Berger. 1991. Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett. 285: 111-114.
9. Forlenza, O. V., B. S. Diniz, L. L. Talib, V. A. Mendonça, E. B. Ojopi, W. F. Gattaz, and A. L. Teixeira. 2009. Increased serum IL-1β level in Alzheimer's disease and mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 28: 507-512.
10. Galimberti, D., C. Fenoglio, C. Lovati, E. Venturelli, I. Guidi, B. Corrà, D. Scalabrini, F. Clerici, C. Mariani, N. Bresolin, and E. Scarpini. 2006. Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. Neurobiol. Aging 27: 1763-1768. (Pubitemid 44572579)
11. Griffin, W. S., L. C. Stanley, C. Ling, L. White, V. MacLeod, L. J. Perrot, C. L. White, III, and C. Araoz. 1989. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. USA 86: 7611-7615. (Pubitemid 19254506)
12. Licastro, F., S. Pedrini, L. Caputo, G. Annoni, L. J. Davis, C. Ferri, V. Casadei, and L. M. Grimaldi. 2000. Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J. Neuroimmunol. 103: 97-102. (Pubitemid 30058259)
13. Rota, E., G. Bellone, P. Rocca, B. Bergamasco, G. Emanuelli, and P. Ferrero. 2006. Increased intrathecal TGF-β1, but not IL-12, IFN-γ and IL-10 levels in Alzheimer's disease patients. Neurol. Sci. 27: 33-39. (Pubitemid 44026855)
14. Blum-Degen, D., T. Müller, W. Kuhn, M. Gerlach, H. Przuntek, and P. Riederer. 1995. Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett. 202: 17-20.
15. Cacabelos, R., M. Barquero, P. García, X. A. Alvarez, and E. Varela de Seijas. 1991. Cerebrospinal fluid interleukin-1β (IL-1β) in Alzheimer's disease and neurological disorders. Methods Find. Exp. Clin. Pharmacol. 13: 455-458.
16. Parachikova, A., M. G. Agadjanyan, D. H. Cribbs, M. Blurton-Jones, V. Perreau, J. Rogers, T. G. Beach, and C. W. Cotman. 2007. Inflammatory changes parallel the early stages of Alzheimer disease. Neurobiol. Aging 28: 1821-1833. (Pubitemid 47539700)
17. Weeraratna, A. T., A. Kalehua, I. Deleon, D. Bertak, G. Maher, M. S. Wade, A. Lustig, K. G. Becker, W. Wood, III, D. G. Walker, et al. 2007. Alterations in immunological and neurological gene expression patterns in Alzheimer's disease tissues. Exp. Cell Res. 313: 450-461. (Pubitemid 46186300)
18. Bertram, L., C. M. Lill, and R. E. Tanzi. 2010. The genetics of Alzheimer disease: back to the future. Neuron 68: 270-281.
19. Bertram, L., M. B. McQueen, K. Mullin, D. Blacker, and R. E. Tanzi. 2007. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 39: 17-23. (Pubitemid 46026496)
20. Harold, D., R. Abraham, P. Hollingworth, R. Sims, A. Gerrish, M. L. Hamshere, J. S. Pahwa, V. Moskvina, K. Dowzell, A. Williams, et al. 2009. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 41: 1088-1093.
21. Hollingworth, P., D. Harold, R. Sims, A. Gerrish, J. C. Lambert,M.M. Carrasquillo, R. Abraham, M. L. Hamshere, J. S. Pahwa, V. Moskvina, et al. 2011. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat. Genet. 43: 429-435.
22. Lambert, J. C., S. Heath, G. Even, D. Campion, K. Sleegers, M. Hiltunen, O. Combarros, D. Zelenika, M. J. Bullido, B. Tavernier, et al. 2009. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 41: 1094-1099.
23. Naj, A. C., G. Jun, G. W. Beecham, L. S. Wang, B. N. Vardarajan, J. Buros, P. J. Gallins, J. D. Buxbaum, G. P. Jarvik, P. K. Crane, et al. 2011. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat. Genet. 43: 436-441.
24. Seshadri, S., A. L. Fitzpatrick, M. A. Ikram, A. L. DeStefano, V. Gudnason, M. Boada, J. C. Bis, A. V. Smith, M. M. Carassquillo, J. C. Lambert, et al. 2010. Genome-wide analysis of genetic loci associated with Alzheimer disease. J. Am. Med. Assoc. 303: 1832-1840.
25. Yoshiyama, Y., M. Higuchi, B. Zhang, S. M. Huang, N. Iwata, T. C. Saido, J. Maeda, T. Suhara, J. Q. Trojanowski, and V. M. Lee. 2007. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53: 337-351. (Pubitemid 46161268)
26. Giuliani, F., A. Vernay, G. Leuba, and F. Schenk. 2009. Decreased behavioral impairments in an Alzheimer mice model by interfering with TNF-α metabolism. Brain Res. Bull. 80: 302-308.
27. McAlpine, F. E., J. K. Lee, A. S. Harms, K. A. Ruhn, M. Blurton-Jones, J. Hong, P. Das, T. E. Golde, F. M. LaFerla, S. Oddo, et al. 2009. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol. Dis. 34: 163-177.
28. Tobinick, E. L., and H. Gross. 2008. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J. Neuroinflammation 5: 2.
29. Forloni, G., F. Demicheli, S. Giorgi, C. Bendotti, and N. Angeretti. 1992. Expression of amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: modulation by interleukin-1. Brain Res. Mol. Brain Res. 16: 128-134.
30. Yang, Y., W. W. Quitschke, and G. J. Brewer. 1998. Upregulation of amyloid precursor protein gene promoter in rat primary hippocampal neurons by phorbol ester, IL-1 and retinoic acid, but not by reactive oxygen species. Brain Res. Mol. Brain Res. 60: 40-49. (Pubitemid 28433193)
31. Li, Y., L. Liu, S. W. Barger, and W. S. Griffin. 2003. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci. 23: 1605-1611. (Pubitemid 36314715)
32. Kitazawa, M., S. Oddo, T. R. Yamasaki, K. N. Green, and F. M. LaFerla. 2005. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J. Neurosci. 25: 8843-8853. (Pubitemid 41384452)
33. Sheng, J. G., S. G. Zhu, R. A. Jones, W. S. Griffin, and R. E. Mrak. 2000. Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo. Exp. Neurol. 163: 388-391. (Pubitemid 30399087)
34. Shaftel, S. S., S. Kyrkanides, J. A. Olschowka, J. N. Miller, R. E. Johnson, and M. K. O'Banion. 2007. Sustained hippocampal IL-1β overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J. Clin. Invest. 117: 1595-1604. (Pubitemid 46871344)
35. Tachida, Y., K. Nakagawa, T. Saito, T. C. Saido, T. Honda, Y. Saito, S. Murayama, T. Endo, G. Sakaguchi, A. Kato, et al. 2008. Interleukin-1β up-regulates TACE to enhance α-cleavage of APP in neurons: resulting decrease in Aβ production. J. Neurochem. 104: 1387-1393. (Pubitemid 351293352)
36. Blurton-Jones, M., M. Kitazawa, H. Martinez-Coria, N. A. Castello, F. J. Müller, J. F. Loring, T. R. Yamasaki, W. W. Poon, K. N. Green, and F. M. LaFerla. 2009. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci. USA 106: 13594-13599.
37. Martinez-Coria, H., K. N. Green, L. M. Billings, M. Kitazawa, M. Albrecht, G. Rammes, C. G. Parsons, S. Gupta, P. Banerjee, and F. M. LaFerla. 2010. Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am. J. Pathol. 176: 870-880.
38. Cribbs, D. H., A. Ghochikyan, V. Vasilevko, M. Tran, I. Petrushina, N. Sadzikava, D. Babikyan, P. Kesslak, T. Kieber-Emmons, C.W. Cotman, and M. G. Agadjanyan.2003. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with β-amyloid. Int. Immunol. 15: 505-514. (Pubitemid 36432403)
39. Head, E., V. Pop, V. Vasilevko, M. Hill, T. Saing, F. Sarsoza, M. Nistor, L. A. Christie, S. Milton, C. Glabe, et al. 2008. A two-year study with fibrillar β-amyloid (Aβ) immunization in aged canines: effects on cognitive function and brain Aβ. J. Neurosci. 28: 3555-3566.
40. Kitazawa, M., D. N. Trinh, and F. M. LaFerla. 2008. Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3β. Ann. Neurol. 64: 15-24.
41. Goedert, M., R. Jakes, and E. Vanmechelen. 1995. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci. Lett. 189: 167-169.
42. Tsoporis, J. N., A. Marks, L. J. Van Eldik, D. O'Hanlon, and T. G. Parker. 2003. Regulation of the S100B gene by α1-adrenergic stimulation in cardiac myocytes. Am. J. Physiol. Heart Circ. Physiol. 284: H193-H203. (Pubitemid 36076286)
43. Langmann, T., R. Mauerer, and G. Schmitz. 2006. Human ATP-binding cassette transporter TaqMan low-density array: analysis of macrophage differentiation and foam cell formation. Clin. Chem. 52: 310-313. (Pubitemid 43185496)
44. Tan, J., T. Town, F. Crawford, T. Mori, A. DelleDonne, R. Crescentini, D. Obregon, R. A. Flavell, and M. J. Mullan. 2002. Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat. Neurosci. 5: 1288-1293. (Pubitemid 35417763)
45. Wong, M. L., and J. Licinio. 1994. Localization of interleukin 1 type I receptor mRNA in rat brain. Neuroimmunomodulation 1: 110-115.
46. Dodart, J. C., K. R. Bales, K. S. Gannon, S. J. Greene, R. B. DeMattos, C. Mathis, C. A. DeLong, S. Wu, X. Wu, D. M. Holtzman, and S. M. Paul. 2002. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat. Neurosci. 5: 452-457. (Pubitemid 34454251)
47. Hartman, R. E., Y. Izumi, K. R. Bales, S. M. Paul, D. F. Wozniak, and D. M. Holtzman. 2005. Treatment with an amyloid-β antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J. Neurosci. 25: 6213-6220. (Pubitemid 40923488)
48. Kotilinek, L. A., B. Bacskai, M. Westerman, T. Kawarabayashi, L. Younkin, B. T. Hyman, S. Younkin, and K. H. Ashe. 2002. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22: 6331-6335. (Pubitemid 35386387)
49. Lee, E. B., L. Z. Leng, B. Zhang, L. Kwong, J. Q. Trojanowski, T. Abel, and V. M. Lee. 2006. Targeting amyloid-β peptide (Aβ) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Aβ precursor protein (APP) transgenic mice. J. Biol. Chem. 281: 4292-4299. (Pubitemid 43847859)
50. Oddo, S., V. Vasilevko, A. Caccamo, M. Kitazawa, D. H. Cribbs, and F. M. LaFerla. 2006. Reduction of soluble Aβ and tau, but not soluble Aβ alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem. 281: 39413-39423. (Pubitemid 46041901)
51. Wang, A., P. Das, R. C. Switzer, III, T. E. Golde, and J. L. Jankowsky. 2011. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-β immunotherapy. J. Neurosci. 31: 4124-4136.
52. Wilcock, D. M., A. Rojiani, A. Rosenthal, G. Levkowitz, S. Subbarao, J. Alamed, D. Wilson, N. Wilson, M. J. Freeman, M. N. Gordon, and D. Morgan. 2004. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci. 24: 6144-6151. (Pubitemid 38891105)
53. Bhaskar, K., M. Konerth, O. N. Kokiko-Cochran, A. Cardona, R. M. Ransohoff, and B. T. Lamb. 2010. Regulation of tau pathology by the microglial fractalkine receptor. Neuron 68: 19-31.
54. Jimenez, S., D. Baglietto-Vargas, C. Caballero, I. Moreno-Gonzalez, M. Torres, R. Sanchez-Varo, D. Ruano, M. Vizuete, A. Gutierrez, and J. Vitorica. 2008. Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's disease: age-dependent switch in the microglial phenotype from alternative to classic. J. Neurosci. 28: 11650-11661.
55. Sheng, J. G., R. A. Jones, X. Q. Zhou, J. M. McGinness, L. J. Van Eldik, R. E. Mrak, and W. S. Griffin. 2001. Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: potential significance for tau protein phosphorylation. Neurochem. Int. 39: 341-348. (Pubitemid 32907398)
56. Basu, A., J. K. Krady, M. O'Malley, S. D. Styren, S. T. DeKosky, and S.W. Levison. 2002. The type 1 interleukin-1 receptor is essential for the efficient activation of microglia and the induction of multiple proinflammatory mediators in response to brain injury. J. Neurosci. 22: 6071-6082. (Pubitemid 35387650)
57. Kim, S. H., C. J. Smith, and L. J. Van Eldik. 2004. Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1β production. Neurobiol. Aging 25: 431-439. (Pubitemid 38317340)
58. Lee, S. C., W. Liu, D. W. Dickson, C. F. Brosnan, and J. W. Berman. 1993. Cytokine production by human fetal microglia and astrocytes: differential induction by lipopolysaccharide and IL-1β. J. Immunol. 150: 2659-2667. (Pubitemid 23127515)
59. de Souza, D. F., M. C. Leite, A. Quincozes-Santos, P. Nardin, L. S. Tortorelli, M. M. Rigo, C. Gottfried, R. B. Leal, and C. A. Gonçalves. 2009. S100B secretion is stimulated by IL-1β in glial cultures and hippocampal slices of rats: likely involvement of MAPK pathway. J. Neuroimmunol. 206: 52-57.
60. Sheng, J. G., K. Ito, R. D. Skinner, R. E. Mrak, C. R. Rovnaghi, L. J. Van Eldik, and W. S. Griffin. 1996. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol. Aging 17: 761-766. (Pubitemid 26348877)
61. Peskind, E. R., W. S. Griffin, K. T. Akama, M. A. Raskind, and L. J. Van Eldik. 2001. Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease. Neurochem. Int. 39: 409-413. (Pubitemid 32907405)
62. Esposito, G., C. Scuderi, J. Lu, C. Savani, D. De Filippis, T. Iuvone, L. Steardo, Jr., V. Sheen, and L. Steardo. 2008. S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells. J. Cell. Mol. Med. 12: 914-927. (Pubitemid 351718070)
63. Masliah, E., E. Rockenstein, A. Adame, M. Alford, L. Crews, M. Hashimoto, P. Seubert, M. Lee, J. Goldstein, T. Chilcote, et al. 2005. Effects of α-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46: 857-868. (Pubitemid 40805347)
64. Levites, Y., P. Das, R. W. Price, M. J. Rochette, L. A. Kostura, E. M. McGowan, M. P. Murphy, and T. E. Golde. 2006. Anti-Aβ42- and anti-Aβ40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J. Clin. Invest. 116: 193-201. (Pubitemid 43121804)
65. Chakrabarty, P., C. Ceballos-Diaz, A. Beccard, C. Janus, D. Dickson, T. E. Golde, and P. Das. 2010. IFN-γ promotes complement expression and attenuates amyloid plaque deposition in amyloid β precursor protein transgenic mice. J. Immunol. 184: 5333-5343.
66. Chakrabarty, P., K. Jansen-West, A. Beccard, C. Ceballos-Diaz, Y. Levites, C. Verbeeck, A. C. Zubair, D. Dickson, T. E. Golde, and P. Das. 2010. Massive gliosis induced by interleukin-6 suppresses Aβ deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J. 24: 548-559.
67. Hickman, S. E., E. K. Allison, and J. El Khoury. 2008. Microglial dysfunction and defective β-amyloid clearance pathways in aging Alzheimer's disease mice. J. Neurosci. 28: 8354-8360.
68. Tanji, K., F. Mori, T. Imaizumi, H. Yoshida, K. Satoh, and K. Wakabayashi. 2003. Interleukin-1 induces tau phosphorylation and morphological changes in cultured human astrocytes. Neuroreport 14: 413-417. (Pubitemid 36337941)
69. Hu, J., F. Castets, J. L. Guevara, and L. J. Van Eldik. 1996. S100b stimulates inducible nitric oxide synthase activity and mRNA levels in rat cortical astrocytes. J. Biol. Chem. 271: 2543-2547.
70. Li, Y., S. W. Barger, L. Liu, R. E. Mrak, and W. S. Griffin. 2000. S100β induction of the proinflammatory cytokine interleukin-6 in neurons. J. Neurochem. 74: 143-150. (Pubitemid 30012764)
71. Li, Y., J. Wang, J. G. Sheng, L. Liu, S. W. Barger, R. A. Jones, L. J. Van Eldik, R. E. Mrak, and W. S. Griffin. 1998. S100β increases levels of β-amyloid precursor protein and its encoding mRNA in rat neuronal cultures. J. Neurochem. 71: 1421-1428. (Pubitemid 28443012)
72. Liu, L., Y. Li, L. J. Van Eldik, W. S. Griffin, and S. W. Barger. 2005. S100B-induced microglial and neuronal IL-1 expression is mediated by cell type-specific transcription factors. J. Neurochem. 92: 546-553. (Pubitemid 40189458)
73. Petzold, A., R. Jenkins, H. C. Watt, A. J. Green, E. J. Thompson, G. Keir, N. C. Fox, and M. N. Rossor. 2003. Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease. Neurosci. Lett. 336: 167-170. (Pubitemid 36050109)
74. Sheng, J. G., R. E. Mrak, K. R. Bales, B. Cordell, S. M. Paul, R. A. Jones, S. Woodward, X. Q. Zhou, J. M. McGinness, and W. S. Griffin. 2000. Overexpression of the neuritotrophic cytokine S100β precedes the appearance of neuritic b-amyloid plaques in APPV717F mice. J. Neurochem. 74: 295-301. (Pubitemid 30012781)
75. Mori, T., N. Koyama, G. W. Arendash, Y. Horikoshi-Sakuraba, J. Tan, and T. Town. 2010. Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease. Glia 58: 300-314.
76. De Ferrari, G. V., and R. T. Moon. 2006. The ups and downs of Wnt signaling in prevalent neurological disorders. Oncogene 25: 7545-7553. (Pubitemid 44885754)
77. Kozlovsky, N., R. H. Belmaker, and G. Agam. 2002. GSK-3 and the neurodevelopmental hypothesis of schizophrenia. Eur. Neuropsychopharmacol. 12: 13-25. (Pubitemid 34098826)
78. Pei, J. J., E. Braak, H. Braak, I. Grundke-Iqbal, K. Iqbal, B. Winblad, and R. F. Cowburn. 1999. Distribution of active glycogen synthase kinase 3b (GSK-3β) in brains staged for Alzheimer disease neurofibrillary changes. J. Neuropathol. Exp. Neurol. 58: 1010-1019. (Pubitemid 29441929)
79. Zhang, Z., H. Hartmann, V. M. Do, D. Abramowski, C. Sturchler-Pierrat, M. Staufenbiel, B. Sommer, M. van de Wetering, H. Clevers, P. Saftig, et al. 1998. Destabilization of β-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature 395: 698-702. (Pubitemid 28475966)
80. He, P., and Y. Shen. 2009. Interruption of β-catenin signaling reduces neurogenesis in Alzheimer's disease. J. Neurosci. 29: 6545-6557.
81. Lucas, J. J., F. Hernández, P. Gómez-Ramos, M. A. Morán, R. Hen, and J. Avila. 2001. Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice. EMBO J. 20: 27-39. (Pubitemid 32099099)